Previous attempts were made to develop ABCB1 inhibitors for clinical use to overcome multidrug resistance, but they failed in clinical trials primarily because the trials did not limit patient selection to those whose tumours were nonresponsive to treatment due to ABC transporter overexpression [28,35]. Here, ABCB1 is linked to neoplasm.